Immunological changes at "small" forms of lesion of the cervical epithelium.

O. P. Lipko, V. V. Bobrytska, L. V. Potapova, N. V. Tkachova


In order to study immunological parameters, including cervical mRNA in patients with persistent papillomavirus infection, 35 patients of the main group (HPV positive) and 42 patients of the control group (HPV negative) were examined. Patients of the main group were divided into three subgroups according to the process prescription and the results of previous immunotropic therapy: IА subgroup – (12 patients) HPV was first isolated, IB (16 patients) - persistence of the virus from one to three years, IC (7 patients) – persistence of the virus from one to three years, immunotropic therapy is ineffective. The level of IL-1, IL-6, IL-8, IL-10, TNF-ɑ, serum interferon, as well as mir25 microRNA expression level was determined. Data have been obtained that the persistence of papillomavirus infection is possible in conditions of deficiency in the level of cytokines IL-1 (45.5%, p<0.05), IL-6 (48.5%, p<0.05), IL-8 (24.2%, p<0.05), increase in the level of TNF-α (37.3%, p<0.05) and a reduced level of serum IFN up to 78.2%. The absence of the effect of HPV elimination is observed in the decrease of the indices from the conventional norm: IL-1 (73.6%, p<0.05), IL-8 (81.3%, p<0.05), IL-10 (25, 0%, p<0.05), TNF-α (77.8%, p<0.05). At the same time, the level of mRNA expression increases by 5.5 (p<0.05) from the median values of the control group. A decrease in the level of humoral immunity along with an increase in mRNA expression can serve as a marker of the resistance of HPV to therapeutic measures and determination the tactics of further therapy of patients with "small” forms of cervical epithelial lesions.


epithelial lesions; cervix; "small forms"; human papillomavirus; microRNA


Zalessky VN,VelikayaNV,Omelchuk ST.[Anti-inflammatory nutrition in the prevention and treatment of chronic non-infectious (including neoplastic) diseases of man. Molecular defense mechanisms of bioactive food components: monograph].Vinnitsa, Nova kniga, 2014;736. Russian.

Tiguntsev VV, Ivanova SA, Serebrov VYu, Bu­kha­reva MB. [Small noncoding RNAs as promising bio­markers: biogenesis and therapeutic strategies]. Bulletin of Siberian Medicine, 2016;15(2):112-26. Russian.

Kovalchuk LV, et al. [Immunology: a workshop]. Textbook, KGMА. 2010;176. Russian.

Caiazza C, Mallardo M. The roles of mir-25 and its targeted genes in development of human cancer. Mic­rona. 2016:5(2):113-9.

Frixa T, Donzellis S, Blandino G. Oncogenetic Micro-RNAs: key-players in malignant transformation. Cancers (Basel) 2015;7(4):2466-85.

GOST Style Citations

  1. Залесский В.Н. Противовоспалительное пита­ние в профилактике и лечении хронических неинфек­ционных (в том числе опухолевых) заболеваний чело­века. Молекулярные защитные механизмы биоак­тив­ных компонентов пищи: монография / В.Н. Залесский, Н.В. Великая, С.Т. Омельчук – Винница: Нова книга, 2014. – 736 с.
  2. Малые некодирующие рнк как перспективные биомаркеры: биогенез и терапевтические стратегии / В.В. Тигунцев, С.А. Иванова, В.Ю. Серебров, М.Б. Бу­харева // Бюлл. Сибир. медицины. – 2016. – Т. 15, № 2. – С. 112-126.
  3. Ковальчук Л.В. Иммунология: практикум: учеб. пособие / Л.В. Ковальчук.– КГМА, 2010. – 176 с.
  4. Caiazza C. The roles of mir-25 and its targeted genes in development of human cancer / C. Caiazza, M. Mallardo // Microna. – 2016. – Vol. 5, N 2. – P. 113-119.
  5. Frixa T. Oncogenetic Micro-RNAs: key-players in malignant transformation / T. Frixa, S. Donzellis, G. Blan­dino // Cancers (Basel). – 2015. – Vol. 7, N 4. – P. 2466-85.



  • There are currently no refbacks.